The DIAMOND Study: Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi for HFrEF

Summary:
This study evaluated the role of Patiromer in enabling patients with heart failure with reduced ejection fraction (HFrEF) and hyperkalemia to maintain optimal RAAS inhibitor therapy. The findings suggested that Patiromer allowed patients to stay on target RAASi doses and had fewer hyperkalemia-related events, but further studies are required to confirm the impact on clinical outcomes.

Produced by: Dr. Ashish Correa, MD and Dr. Anu Lala, MD
Reviewed by: Dr. Teodora Donisan, Dr. Amit Goyal

CardioNerds Infographics

Explore our comprehensive collection of infographics, categorized by cardiovascular topics such as heart failure and transplantation, arrhythmias and electrophysiology, cardio-obstetrics, cardiovascular imaging, congenital heart disease, prevention, coronary artery disease, critical care, hypertension, pericardial disease, pulmonary hypertension, valvular heart disease, vascular disease, women’s cardiovascular health, diversity, inclusion, and more!

Feel free to download and share these visuals in presentations or on social media. Please use the infographics as provided—without altering or cropping out the creators’ credit.

For even more learning, explore the CardioNerds Tweetorial Page, featuring a curated collection of educational tweetorials!